>>Signaling Pathways>> GPCR/G protein>> GHSR>>TM-N1324

TM-N1324 (Synonyms: Compound 1324, Cpd1324)

Catalog No.GC31074

TM-N1324는 G-단백질 결합 수용체 39(GPR39)의 작용제이며 Zn2+가 있을 때 EC50이 9nM/5nM이고 Zn2+가 없을 때 280nM/180nM입니다. 인간/쥐 GPR39용.

Products are for research use only. Not for human use. We do not sell to patients.

TM-N1324 Chemical Structure

Cas No.: 1144477-35-9

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$98.00
재고 있음
1mg
US$46.00
재고 있음
5mg
US$111.00
재고 있음
10mg
US$213.00
재고 있음
50mg
US$853.00
재고 있음
100mg
US$1,622.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

TM-N1324 is an agonist of G-Protein-Coupled Receptor 39 (GPR39) with EC50s of 9 nM/5 nM in the presence of Zn2+, and 280 nM/180 nM in the absence of Zn2+ for human/murine GPR39.

TM-N1324 activates human GPR39 with high efficacy and potencies of 280 nM and 9 nM in the absence and presence of Zn2+, respectively. TM-N1324 has similar potencies on murine GPR39, 180 nM and 5 nM. TM-N1324 is also found to have promising in vitro ADME properties. TM-N1324 has reasonably good aqueous solubility (65 μM at pH 7.0). Measurements of somatostatin confirms that the GPR39 agonist TM-N1324 increases somatostatin release by 53%[1].

[1]. Frimurer TM, et al. Model-Based Discovery of Synthetic Agonists for the Zn2+-Sensing G-Protein-Coupled Receptor 39 (GPR39) Reveals Novel Biological Functions. J Med Chem. 2017 Feb 9;60(3):886-898.

리뷰

Review for TM-N1324

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TM-N1324

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.